FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/Investigational Peptide CS060380 Shows Promise in Combating MASH and Obesity
연구 도서관으로 돌아가기

Investigational Peptide CS060380 Shows Promise in Combating MASH and Obesity

May 25, 2026
Share
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 AI 도구를 사용하여 생성된 요약입니다. 최근 게시된 뉴스 항목이나 임상 시험 목록의 요약으로, 피테이드 연구 커뮤니티에게 빠르고 접근하기 쉬운 개요를 제공하기 위해 작성되었습니다. 정확성을 위해서는 항상 아래 링크로 연결된 원문을 참조하십시오.

Investigational Peptide CS060380 Shows Promise in Combating MASH and Obesity

A new clinical trial aims to test the efficacy and safety of a novel investigational peptide, CS060380, when used alongside semaglutide for treating patients with metabolic dysfunction-associated steatohepatitis (MASH) and obesity. This Phase II study is an exciting development in the world of peptide therapy as it explores potential new avenues to address serious health conditions that are becoming increasingly common.

Background

Metabolic dysfunction-associated steatohepatitis, or MASH, is a condition characterized by fat accumulation in the liver, leading to inflammation and damage. It’s often associated with obesity, type 2 diabetes, and metabolic syndrome. Currently available treatments for MASH are limited and primarily focus on addressing underlying risk factors such as weight management and blood sugar control.

Semaglutide has been shown to be effective in managing obesity and improving glycemic control, but its impact on liver health specifically is still under investigation. This new study seeks to expand the understanding of semaglutide’s potential benefits when combined with CS060380—a peptide being developed by Cascade Pharmaceuticals, Inc.

Key Details

The study, titled "A Study of CS060380 Tablets in Patients With MASH and Obesity," is recruiting participants across multiple sites. Researchers will monitor the effects of a combination therapy involving semaglutide and CS060380 compared to those who receive placebo treatments.

This trial is crucial as it targets two major public health concerns: obesity and liver disease. The research aims to determine if the combined use of these peptides can improve outcomes for patients with MASH, offering hope to millions worldwide who suffer from this debilitating condition.

The study duration spans up to 54 weeks, providing ample time to assess long-term benefits and safety profiles associated with the new investigational drug CS060380. Participants will be closely monitored throughout the trial period to gather comprehensive data on the effectiveness of this novel treatment approach.

Key Takeaways

  • Novel Combination Therapy: The study explores the potential synergy between semaglutide and CS060380 for treating MASH.
  • Patient Recruitment: Researchers are actively recruiting adults who suffer from both obesity and metabolic dysfunction-associated steatohepatitis.
  • Long-term Monitoring: Participants will be followed for up to 54 weeks, ensuring detailed insights into the safety and efficacy of the treatment over time.
  • Potential for Breakthroughs: This research could pave the way for new therapeutic options in managing liver health issues linked with obesity.

What This Means

For the peptide community, this study represents a significant step forward in exploring innovative treatments for complex metabolic disorders. The combination therapy approach offers promising possibilities for improving patient outcomes and quality of life. If successful, CS060380 could become an important addition to the toolkit of medical professionals dealing with MASH and obesity.

---

Source: ClinicalTrials.gov — Published 2026-05-20

This article is for informational purposes only and does not constitute medical advice.

편집자의 주석

이 분석은 AI 도구를 사용하여 생성되었으며 Peptide Contacts 편집팀으로부터 검토되었습니다. 정확성을 위해 항상 원문을 참조하십시오. 원본 출처 전체 세부사항, 방법론 및 데이터는 여기에서 확인하실 수 있습니다.

Peptide Contacts는 정보 제공 목적으로만 피테이드 연구 요약을 큐레이션합니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 건강 결정을 내릴 때 항상 자격 있는 의료 전문가와 상담하십시오.

Comments

Sign in to join the discussion

이 기사는 AI 도구를 사용하여 생성되었으며 정확성을 보장하지 않습니다. 정보 제공 목적으로만 제공되며 의학적 조언으로 간주되지 않습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하십시오.